-+ 0.00%
-+ 0.00%
-+ 0.00%

Guardant Health study finds blood tests help assess recurrence risk after colorectal cancer metastasis surgery

PUBT·11/10/2026 21:07:59
Listen to the news
Guardant Health study finds blood tests help assess recurrence risk after colorectal cancer metastasis surgery
  • Guardant Health announced published PRECISION study results showing its liquid biopsy tests improved recurrence-risk assessment following surgery for colorectal cancer metastases.
  • The Japanese study enrolled 130 patients, pairing pretreatment Guardant360 Liquid genomic profiling with postoperative Guardant Reveal testing for residual cancer.
  • Combined testing identified three distinct recurrence-risk groups, potentially supporting more personalized treatment strategies.
  • Findings require prospective validation in an interventional study before informing treatment decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101605BIZWIRE_USPR_____20261109_BW113122) on November 10, 2026, and is solely responsible for the information contained therein.